In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0013837 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Nour M Alkashef und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Cryptococcus neoformans, Cryptococcosis, Antifungal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Cryptococcosis is an opportunistic fungal infection affecting individuals with compromised immunity, particularly those with HIV. The limited accessibility to effective treatments and treatment-related toxicities underline the need for more effective therapeutic options. In this study, we conducted a whole-cell screening of ~ 3,700 FDA-approved drugs and clinical molecules against the Cryptococcus neoformans H99 strain. The anti-mycobacterial agent SQ109 was identified as one of the most potent hits, with broad antifungal activity. SQ109 exhibited potent activity against Cryptococcus spp . , with an MIC90 of 4 μg/mL. In the time-kill assay, SQ109 demonstrated a fungicidal activity on proliferating cryptococcal cells in a concentration-dependent manner. Unlike fluconazole (FLC) and flucytosine (5-FC), C. neoformans showed a negligible tendency to develop resistance to SQ109 during frequent passaging. Furthermore, SQ109 exhibited a potent efficiency in the murine model of cryptococcal infection, resulting in a 50% survival rate among animals treated with 25 mg/kg for 10 consecutive days. The transcriptomic analysis revealed that SQ109 disrupts ergosterol biosynthesis, affecting membrane integrity and oxidative homeostasis. Additionally, molecular docking and structural analysis indicated that squalene synthase protein ERG9 is the most likely target of SQ109 within the ergosterol biosynthesis machinery of cryptococcal cells. Notably, SQ109 potentiates the activity of the standard antifungal FLC, as well as other ergosterol inhibitors, with a fractional inhibitory concentration Index (ΣFICI) ranging from 0.38 to 1. These findings highlight the therapeutic potential of SQ109 in combating cryptococcal infections, both as a standalone therapy and as an adjuvant to FLC monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
- Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
- Department of Biomedical Sciences, Edward Via College of Osteopathic Medicine (VCOM), Blacksburg, Virginia, United States of America.
- Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana, United States of America.
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, United States of America.
- Department of Biochemistry, Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, Virginia, United States of America.
ORCID-Profile: Nour M Alkashef, Mohamed N Seleem
Förderung
- NIAID NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Alkashef, N. M., Salama, E. A., Anandakrishnan, R., Hazbun, T. R., Hoernig, M. V., Brown, A. M., Lawrence, C. B., & Seleem, M. N. (2025). In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013837
Vancouver
Alkashef NM, Salama EA, Anandakrishnan R, Hazbun TR, Hoernig MV, Brown AM, et al. In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013837
BibTeX
@article{Alkashef2025,
author = {Alkashef, Nour M and Salama, Ehab A and Anandakrishnan, Ramu and Hazbun, Tony R and Hoernig, Micah V and Brown, Anne M and Lawrence, Christopher B and Seleem, Mohamed N},
title = {In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0013837}
}
EUVIMED